We validated KDM6A/KDM6B as the target of GSK-J4 since KDM6A/KDM6B genetic depletion had a remarkably similar effect to GSK-J4 on cisplatin-mediated anti-tumor activity and transcriptome alterations. Here, KDM6A is linked to neoplasm.